



Spire Healthcare

3 Dorset Rise
London
EC4Y 8EN

Tel 0800 169 1777
Fax 020 7427 9001

www.spirehealthcare.com

SHAREHOLDER REFERENCE NUMBER

This letter is important and requires your immediate attention.

If you are in any doubt as to the contents of this letter or what action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000, if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.

If you sell, have sold or otherwise transferred all of your ordinary shares in Spire Healthcare Group plc, please send this letter at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for delivery to the purchaser or the transferee. If you sell, have sold or otherwise transferred only part of your holding of ordinary shares in Spire Healthcare Group plc, you should retain these documents and contact the bank, stockbroker or other agent through whom the sale or transfer was effected. However, this letter is not for release, publication or distribution in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so might constitute a violation of applicable laws or regulations of that jurisdiction and must not be forwarded, transmitted or sent, in whole or in part, to or into any such jurisdiction.

29 September 2026

To: Spire Healthcare Group plc shareholders (**Spire Shareholders**) with shares held on their behalf through the Spire Healthcare Group plc Nominee Service (**CSN**)

Notification of publication of important documentation in relation to the final* recommended acquisition of Spire Healthcare Group plc by Tulip UK Bidco Limited

On 5 September 2026 the board of directors of Spire Healthcare Group plc (the **Company**) and Tulip UK Bidco Limited (**Bidco**) announced that they had reached agreement on the terms of a recommended cash offer, pursuant to which Bidco (a newly formed company to be indirectly owned by a Consortium including (i) funds managed or advised by Toscafund Asset Management LLP; (ii) funds managed or advised by THCP Advisory Limited; and (iii) funds managed or advised by Ares Management Limited) will acquire the entire issued and to be issued ordinary share capital of the Company that the Consortium does not already own (the **Acquisition**). The Acquisition is to be implemented by means of a court-sanctioned scheme of arrangement (the **Scheme**) under Part 26 of the Companies Act 2006 (the **Act**).

The next step in the process is for Eligible Spire Shareholders to vote on the Scheme and, accordingly, certain documents relating to voting are now being sent or made available to Spire Shareholders.

** The financial terms of the Cash Offer and the Alternative Offer are final. Bidco may not revise the Cash Offer or the Alternative Offer other than in exceptional circumstances and only with the prior consent of the*

Panel. Bidco reserves the right to elect to implement the Acquisition by way of a Takeover Offer as an alternative to the Scheme, subject to obtaining the consent of the Panel and subject to the terms of the Co-operation Agreement.

Documents available

The purpose of this letter is to notify you that the circular relating to the Scheme (the ***Scheme Document***), which includes a copy of the Scheme itself, copies of the notices convening the Court Meeting and the General Meeting and an explanatory statement in compliance with section 897 of the Act, is available for inspection, subject to certain restrictions relating to persons in or resident in Restricted Jurisdictions, at www.investors.spirehealthcare.com.

Terms and expressions used but not defined in this letter have the same meaning as in the Scheme Document.

Action to be taken

In order to become effective, the Scheme requires approval at two meetings – the Court Meeting and the General Meeting – both of which are anticipated to be held at 3 Dorset Rise, London EC4Y 8EN. The Court Meeting will start at 12.00 p.m. (London time) and the General Meeting will start at 12.15 p.m. (London time) (or as soon thereafter as the Court Meeting has concluded or been adjourned).

It is expected that the latest time for receipt of online voting instructions by any Spire Shareholder holding through the Equiniti Corporate Sponsored Service is 12.00 p.m. (London Time) on 27 October 2026 for the Court Meeting and 12.15 p.m. (London Time) on 27 October 2026 for the General Meeting.

It is expected that the latest time at which you may instruct transfer of your Scheme Shares from the Equiniti Corporate Sponsored Nominee Service to your own name will be 1.00 p.m. on the date that is at least 10 Business Days prior to the date of the Court Hearing but are strongly encouraged to do this as soon as possible.

You can lodge your proxy appointments at www.shareview.co.uk by logging in to your Shareview Portfolio using your usual username and password. Once logged in simply click "View" on the "My Investments" page, click on the link to vote, then follow the on-screen instructions. To register for a Shareview Portfolio, go to www.shareview.co.uk and follow the instructions. Your shareholder reference number can be found at the top of this letter.

It is important that, for the Court Meeting in particular, as many votes as possible are cast, so that the Court may be satisfied that there is a fair and reasonable representation of the opinion of Eligible Spire Shareholders.

You are therefore strongly advised to submit instructions for the Court Meeting and the General Meeting as soon as possible.

Scheme Document

The Company draws your attention to the 'Action to be taken' sections starting on page 11 and paragraph 18 of Part II (*Explanatory Statement*) of the Scheme Document for details of how to vote. The Notice of Court Meeting is set out in Part XIII of the Scheme Document. The Notice of General Meeting is set out in Part XIV of the Scheme Document.

This letter is not a summary of the information and proposals set out in the Scheme Document and should not be regarded as a substitute for reading the Scheme Document in full. You should read the Scheme Document and the accompanying documents carefully before making a decision in relation to the Scheme or the Acquisition (including the Alternative Offer).

Shareholder helpline

If you have any questions in relation to this letter, the Scheme Document, the Meetings, or the completion and return of the Forms of Proxy (or appointment of a proxy online or electronically) or the Form of Election or any administrative matters in connection with the Acquisition, please telephone Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except UK public holidays) on +44 (0) 371 384 2899 (please use the country code if calling from outside the UK). For deaf and speech impaired shareholders, Equiniti welcomes calls via Relay UK. Please see www.relayuk.bt.com for more information. Calls to the Shareholder Helpline from outside the UK will be charged at applicable international rates. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The Shareholder Helpline cannot provide advice on the merits of the Acquisition (including the Alternative Offer) nor give any financial, legal or tax advice.

Yours faithfully

Mantraraj Budhdev

Group General Counsel and Company Secretary

Publication on a website

Copies of this letter and the Scheme Document (as well as a number of supporting documents) are available, subject to certain restrictions relating to persons in, or resident in, Restricted Jurisdictions, on the Company's website at www.investors.spirehealthcare.com. For the avoidance of doubt, the content of the Company's website is not incorporated into, and does not form part of, this letter.

Responsibility statement

The Company Directors accept responsibility for the information contained in this letter. To the best of the knowledge and belief of the Company Directors (who have taken all reasonable care to ensure that such is the case), the information (including any expressions of opinion) contained in this letter is in accordance with the facts and does not omit anything likely to affect the import of such information.

Provision of addresses, electronic addresses and other details

Please be aware that addresses, electronic addresses and certain other information provided by you for the receipt of communications from the Company (e.g. elections to receive communications in a particular form) may be provided to Bidco during the offer period as required under Section 4 of Appendix 4 of the Code.

Right to request hard copies

You may request a copy of this letter, the Scheme Document and any information incorporated into them by reference to another source in hard copy form by writing to Equiniti Limited, Highdown House, Yeoman Way, Worthing, West Sussex, BN99 6DA, United Kingdom or by calling them on +44 (0) 371 384 2899.

Neither this letter nor the Scheme Document (nor any information incorporated into them by reference to another source) will be provided in hard copy form unless such a request is made.

Persons with information rights should contact their nominee/broker or custodian, and may not make the request through the contacts set out above.

You may also request through the contacts above or, in the case of persons with information rights, by contacting your nominee/broker or custodian, that all future documents, announcements and information sent to you in relation to the Acquisition should be sent to you in hard copy form.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code any person who is interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company; and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th Business Day following the commencement of the offer period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th Business Day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company; and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the Business Day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of the Code).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.